- Matica Biotechnology has developed a high-resolution ion-exchange chromatography (IEX) method to analyse the ratio of full and empty AAV8 viral vector capsids.
Matica Biotechnology, a contract development and manufacturing organization (CDMO) specialising in viral vectors, has unveiled a new high-resolution ion-exchange chromatography (IEX) method designed to improve the analysis of AAV8 (Adeno-Associated Virus 8) viral vector capsids. This advancement addresses a key challenge in cell and gene therapy (CGT), where the presence of non-functional viral vectors can impair drug efficacy.
The method, which was developed by Matica Bio’s analytical team, significantly enhances the resolution between full and empty viral vector capsids, which are typically difficult to distinguish in traditional analyses. With a resolution of at least 10, the method greatly surpasses the industry average of 0.5 to 2, and meets the FDA’s minimum requirement of 2. This new technology offers an efficient, cost-effective alternative to traditional methods such as AUC and mass spectrometry, which can be expensive for both CDMOs and biotech companies.
“We are excited to bring this innovative solution to our clients,” said Dr. Daniel Mitchell, Head of Analytical Development and Quality Control at Matica Bio. “Our approach simplifies the analysis process, aligns with regulatory expectations, and reduces the need for costly equipment.”
The IEX method, developed after an intensive six-month study, offers improved accuracy and precision while also reducing the time required for analysis, completing tests in just 30 minutes. This technology is already being employed in various CGT programs and sets the stage for further advancements in the field. Matica Bio is also looking to extend the method to additional viral vectors, including other AAV serotypes and lentiviruses.
Paul Kim, CEO of Matica Bio, emphasised the company’s commitment to developing solutions that reduce time and cost, while maintaining high-quality standards for its biotech and pharmaceutical partners. As the company continues to expand its service offerings, this development strengthens its position in the viral vector manufacturing space.
Overview of outsourcing trends 
